





PART THE CLOUD

IMPACT REPORT 2025



translational research program in partnership with



A LETTER FROM OUR FOUNDER

Dear Friends:

Thank you so much for joining me on what continues to be a truly extraordinary journey – a long, often difficult, but ultimately beautiful and wonderful journey thanks to you and the Alzheimer's Association.

Before we started Part the Cloud in 2012, the main emotions Alzheimer's triggered in me were profound sadness and helplessness. I had already lost my father to the disease, and I was beginning to lose my mother as well. To sit there and watch it happen and not be proactive would have shattered me. That's why, with a friend's encouragement, I began to reach out to you and others who also have been personally touched by the disease to raise money for Alzheimer's research.

Today, the main emotions I feel are pride, excitement and profound gratitude. Together, with the Part the Cloud Steering Committee and our supporters, we have created a global movement that has generated **more than \$85 million and funded 68 clinical trials of innovative potential treatments** across the globe in nine countries. The biological targets are diverse, which is important given the growing consensus that effective treatment and prevention of Alzheimer's is likely to be a personalized combination of two or more interventions targeting different aspects of the disease.

With the promise of precision medicine in mind, I am thrilled to share that we raised more than \$20 million for our **Part the Cloud Gene Targeting Challenge** through our 2024 gala and other fundraising efforts. Approaches that increase or decrease levels of different genes that play a role in Alzheimer's is a key approach for therapy development. One way to do this is with gene therapy - which is on the leading edge of medical research, and I was excited to hear directly from Part the Cloud grantee Mark Tuszynski, Ph.D., at the Alzheimer's Association International Conference® 2024 (AAIC®) Global Immersion Experience in Philadelphia. Dr. Tuszynski is conducting the first clinical trial of a gene therapy involving brain-derived neurotrophic factor (BDNF) for Alzheimer's, and early results are encouraging. The Gene Targeting Challenge was created to do what Part the Cloud does best: invest in big, bold ideas that will move the needle in our quest to end Alzheimer's and all other dementia.

After initial funding from Part the Cloud, grant recipients have gone on to receive **more than \$1.6 billion in follow-on funding** from the federal government, venture capital firms and other sources, including the Alzheimer's Association. In fact, I am thrilled to share that Joseph Foss, M.D., received a second Part the Cloud grant this past year to take his study of an experimental inflammation-reducing drug to the next phase. Brain inflammation continues to be a promising focus of Alzheimer's research, and I was privileged to tour the lab that's conducting another Part the Cloud-funded project in this area as part of a special New York City experience the Alzheimer's Association offered for philanthropic supporters this past fall.

In this report, you'll read more about the new Gene Targeting Challenge, as well as Part the Cloud's current global impact on the Alzheimer's drug pipeline broadly.

Thank you for your steadfast support. Together we will Part the Cloud!

Warmly,



Mikey Hoag



A LETTER FROM ALZHEIMER'S ASSOCIATION PRESIDENT & CEO

Dear Friends,

We've reached a moment many people once only dreamed of: we now have access to multiple disease-modifying treatments for people at early stages of Alzheimer's. Consider that in the 2023 edition of this report, we celebrated the first traditional approval of a disease-modifying treatment. Now, just a short time later, there are two. What incredible progress.

These treatments are giving people more hope than ever before. For those facing the early stages of Alzheimer's or mild cognitive impairment, multiple treatments mean options and hope for more time. For others, this moment represents hope for the future — that additional treatments, diagnostic tools, prevention strategies and life-changing breakthroughs for all communities are within reach.

As hopeful as we are, we continue to feel the urgency of today. Nearly 7 million people in the US are living with Alzheimer's, and 11 million more provide unpaid care for a family member or friend with dementia. As our nation ages, the impact of this disease is expected to grow, with an estimated 13.8 million people projected to be living with the disease in 2060.

Your generous support of Part the Cloud bolsters our hope for the future. By funding high-risk, high-reward research projects, Part the Cloud is enabling some of the brightest minds in science to explore bold, innovative ideas. These ideas have the potential to accelerate the pace of discovery, drive science forward, and move us ever closer to breakthroughs that could change the lives of people around the world.

We are grateful to you, to our visionary Part the Cloud founder, Mikey Hoag, and to our dedicated Part the Cloud Steering Committee for believing that a transformed future in Alzheimer's and dementia is possible — and for investing in that future. Thank you for all that you do to help us accelerate the pace of progress.

Sincerely,



Joanne Pike, DrPH



PART THE CLOUD

\$85 MILLION
SINCE 2012

\$1.6 BILLION
FOLLOW-ON-FUNDING

68 GLOBAL
PROJECTS

EVENT HIGHLIGHTS

The Part the Cloud Gala was held on Friday, April 19, 2024, at a private residence in Woodside, CA, and raised over \$17 million to support Part the Cloud's mission to accelerate research for Alzheimer's disease and related dementias at a faster pace.

The evening was filled with spectacular moments. Special thanks to Bob Fitzgerald for assisting with the Fund a Need, which raised over \$1.4 million in the room. Beyond the amount of funds raised, we were honored to have Sarah Rafferty host the evening and hear from Nicole Hotlhuis and Doug Inamine about their journey with this disease. The evening ended on a high note with an incredible musical performance by GRAMMY-winning multi-instrumentalist, songwriter and performer, Jon Batiste.

The 2024 Part the Cloud Steering Committee members included Ellen Drew, Dana Eckert, Sue Foley, Stephanie Harman, Mikey Hoag, Lauren Koenig, Anne Lawler, Lisa Mooring, Heather Pietsch, Debbie Robbins, Paula Robichaud, and Mary Stevens.

We look forward to hosting a Luncheon in 2026. More information and details will be listed on our website closer to the date. In the meantime, we continue to raise funds and move the needle forward by investing in clinical research.



Co-chairs Sue Foley and Lauren Koenig



Ronnie Lott and Joe Montana



Part the Cloud Steering Committee



Sarah Rafferty



Jon Batiste



Ted Sarandos and Reed Hastings

Photographer: Drew Altizer Photography

TRANSLATIONAL RESEARCH GRANT RECIPIENTS

Part the Cloud awards grants to scientists focusing on a wide range of research areas.



Metabolic Function

how neurons
process energy



Amyloid Plaques and Tau Tangles

hallmarks of
Alzheimer's disease



The Immune Response, Misfolded Proteins and Growth Factors in the Brain

how the brain heals



Cell Signaling and Communication

how brain cells talk to
one another



Vascular

blood vessels and
blood flow to the brain



Oxidative Stress

imbalance between oxidants
and antioxidants



Cell Senescence

how cells age, and how to address
the effects of cellular aging



Genome Sequencing

gene mapping

GENOME SEQUENCING

Michael Weiner, M.D.

University of California at San Francisco -
San Francisco, CA

**Part the Cloud supported, in part, the Whole
Genome Sequencing Alzheimer's Disease
Neuroimaging Initiative (WGS-ADNI), a project to
sequence the whole genome of more than
800 individuals.**

CELL SENESCENCE

James Kirkland, M.D., Ph.D.

Mayo Clinic - Rochester, MN

ALSENITE: An Open-Label Pilot Study of Senolytics for Alzheimer's Disease

Maurice Zauderer, Ph.D.

Vaccinex, Inc. - Rochester, NY

SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease

IMMUNE RESPONSE, MISFOLDED PROTEINS AND GROWTH FACTORS

Steven Arnold, M.D.

Massachusetts General Hospital - Boston, MA

BCG Immunization Effects on Biomarkers of Inflammation/Immune Response and Alzheimer's Disease

John Sedivy, Ph.D.

Brown University - Providence, RI

Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of Alzheimer's Disease

Hung-Kai (Kevin) Chen, M.D., Ph.D.

Elixiron Immunotherapeutics Inc. - Taipei, Taiwan

Modulating Neuroinflammation by Targeting Microglia with CSF1R Inhibitor EI1071

Mark Tuszynski, M.D.

University of California at San Diego - San Diego, CA

A Clinical Trial of BDNF Gene Therapy in Alzheimer's Disease

Two-time grant winner

Joseph Foss, M.D.

NeuroTherapia, Inc. - Cleveland, OH

A Phase I Single Ascending Dose Safety and Pharmacokinetic Study of NTRX-07

Linda Van Eldik, Ph.D.

University of Kentucky - Lexington, KY

Phase 1b MAD Study of a Novel Drug (MW189) Targeting Neuroinflammation

Two-time grant winner

Joseph Foss, M.D.

NeuroTherapia, Inc. - Cleveland, OH

A Phase IIa study of NTRX-07 in Alzheimer's patients

Manfred Windisch, Ph.D.

Neurokin Therapeutics, LLC - Philadelphia, PA

Phase 1 Study of MW150: Novel Stress Kinase Inhibitor Candidate

Two-time grant winner

Franz Hefti, Ph.D.

Proclara Biosciences - Cambridge, MA

Phase 1 Study with NPT088, A Fusion Protein to Treat Alzheimer's Disease

Jared Robert Brosch, M.D.

Indiana University School of Medicine - Indianapolis, IN

Niacin Treatment of Mild-Moderate Alzheimer's Disease

METABOLIC FUNCTION

Michal Schnaider Beer, Ph.D.

Sheba Medical Center - Ramat Gan, Israel, and
Icahn School of Medicine at Mount Sinai -
New York, NY

*Intranasal Insulin and Dulaglutide for Cognition in
Metabolic Syndrome MCI*

Suzanne Craft, Ph.D.

Wake Forest University Health Sciences -
Winston-Salem, NC

*A Phase IIA Trial of Empagliflozin and Intranasal
Insulin for MCI/AD*

Stephen Cunnane, Ph.D.

University of Sherbrooke - Quebec, Canada

*Proof of Mechanism of a New Ketogenic Supplement
Using Dual Tracer PET*

Two-time grant winner

Stephen Cunnane, Ph.D.

University of Sherbrooke - Quebec, Canada

RCT with a New Ketogenic Salt in MCI

Two-time grant winner

Paul Edison, M.B.B.S., F.R.C.P., Ph.D.

Imperial College London -
London, United Kingdom

*Evaluating Oral Semaglutide as a Treatment for
Alzheimer's Disease*

Two-time grant winner

Mitchel Kling, M.D.

University of Pennsylvania - Philadelphia, PA

A biomarker-based trial in MCI/AD

*Product as tested in this work did not go forward

Giulio Maria Pasinetti, M.D., Ph.D.

Icahn School of Medicine at Mount Sinai -
New York, NY

*BDPP Treatment for Mild Cognitive Impairment
and Prediabetes*

Stefano Sensi, M.D., Ph.D.

Universita degli Studi Gabriele d'Annunzio
di Chieti e Pescara - Chieti, Italy

Extenzin-Based Therapy for MCI Subjects

Russell Swerdlow, M.D.

University of Kansas Medical Center - Fairway, KS

*Trial of Oxaloacetate in Alzheimer's Disease
(TOAD) Study*


“Part the Cloud propels the global research community and allows it to explore innovative avenues of research that can accelerate needed treatments.”

Maria C. Carrillo, Ph.D.

Chief Science Officer and Medical Affairs Lead, Alzheimer's Association

FOLLOW-ON FUNDING

Part the Cloud advances research: From more than \$70 million in funding PTC has awarded, grant recipients have gone on to receive more than \$1.6 billion in follow-on funding from the U.S. federal government, venture capital firms and other sources.



Follow-On Funding comes from a variety of sources including:

- Foundations (2.0%)
- Private (7.4%)
- Government (45.1%)
- Venture/Corporate (30.0%)
- Indirect (15.5%)

Indirect sources are government, foundation, corporate, venture capital, and individual support that is indirectly related to the Part the Cloud Translational award.

AMYLOID AND TAU

Adam L. Boxer, M.D., Ph.D.

University of California at San Francisco -
San Francisco, CA

*Phase I Multiple Ascending Dose Trial of the MT
Stabilizer TPI-287 for AD***

Dale E. Bredesen, M.D.

Buck Institute for Research on Aging - Novato, CA

*An Exploratory Safety, PK/PD, and Preliminary
Efficacy Study of F03 in MCI***

Ross Paterson, Ph.D.

Institute of Neurology, University College London
- London, United Kingdom

*Capturing Tau Kinetics in a Clinical Trial of ASO
NI0752 in Alzheimer's*

Tim West, Ph.D.

C2N Diagnostics - St. Louis, MO

*A Single Ascending Dose Double Blinded Placebo
Controlled Study of C2N-8E12***

Dieter Willbold, Ph.D.

Research Center Juelich GmbH - Jülich, Germany

*Placebo Controlled Multi-Ascending Dose
[Targeting Protein Aggregation] Phase 1 Study in
Healthy Volunteers*

Lawren VandeVrede, M.D., Ph.D.

University of California, San Francisco - San
Francisco, CA

*Study of a Tau Antisense Oligonucleotide in
Corticobasal Syndrome (STACS)*

***Trials or development not advanced*

CELL SIGNALING AND COMMUNICATION

Frank Longo, M.D., and Anne Longo

Pharmatrophix, Inc. - Stanford, CA

Phase I Trial for P75 Receptor Ligand

Charbel Moussa, Ph.D.

Georgetown University - Washington, D.C.

Bosutinib Effects on Safety, Biomarkers and Clinical Outcomes in DLB

Paul A. Newhouse, M.D.

Vanderbilt University - Nashville, TN

Phase 1 Testing of a Muscarinic M1 PAM for Alzheimer's Disease

Two-time grant winner

Ahmad Salehi, M.D., Ph.D.

Palo Alto Institute for Research and Education, Inc.
- Palo Alto, CA

Improving β 2 Adrenergic Signaling in Alzheimer's Disease

Keith Vossel, M.D., M.Sc

University of California at San Francisco and
Gladstone Institute for Neurological Disease -
San Francisco, CA

*Phase 2a Levetiracetam Trial for AD-Associated
Network Hyperexcitability*

Nawaf Yassi, M.D., Ph.D.

University of Melbourne - Parkville, Australia
S-Adenosyl Methionine for Alzheimer's Disease

VASCULAR AND OXIDATIVE STRESS

Jan Johansson, M.D., Ph.D.

Artery Therapeutics, Inc. - San Ramon, CA

Human proof of concept of ABCA1 agonist CS6253 treatment

Krista L. Lanctôt, Ph.D.

Sunnybrook Research Institute - Toronto, Canada

Linking GSH and Cognitive Response: A Pilot Phase 2a Study of NAC in VCIND

Two-time grant winner

Amala Soumyanath, Ph.D., and Joseph Quinn, M.D.

Oregon Health and Science University -
Portland, OR

Safety and Target Engagement of Centella Asiatica in Cognitive Impairment


Whitney Wharton, Ph.D.

Emory University - Atlanta, GA

Mechanistic Potential of Antihypertensives in Preclinical Alzheimer's

DRUG PIPELINE

Getting potential treatments faster: propelling high-risk, high-reward research into clinical trials that are aimed at uncovering underlying brain cell changes, timely diagnosis and new treatments for Alzheimer’s and all dementia.





CHALLENGES

Challenges focus on a specific topic and are awarded biennially.

RESCUE AND NEURODEGENERATION

The Part the Cloud to RESCUE (REverse, reStore, Cease and UndErstand) Brain Cell Degeneration in Alzheimer's disease challenge aims to accelerate the discovery and testing of innovative compounds to be used for interventions in the earliest stages of neurodegeneration-dementia-Alzheimer's disease. Presently, there are no effective interventions to delay or prevent the progression of the neurodegenerative processes that underlie the disabling symptoms of Alzheimer's dementia.

From 45 proposals, six researchers were awarded \$1 million each to develop their research over a two-year period.

Roberta Diaz Brinton, Ph.D.

University of Arizona - Tucson, AZ

Advancing Allopregnanolone as a Regenerative Therapeutic for Alzheimer's

Rafael de la Torre, PharmD, Ph.D.

Institute Mar of Medical Investigations -
Barcelona, Spain

Cognitive Decline in Early Stages of AD After EGCG and a Multimodal Therapy

Xue Hua, Ph.D.*

Athira Pharma, Inc. - Seattle, WA

Phase 2a Alzheimer's Trials of a Novel Neurotrophic Activator, NDX-1017

**No longer an employee of the company; the ongoing trials are overseen by the Athira Leadership Team*

Paul A. Newhouse, M.D.

Vanderbilt University - Nashville, TN

*M1-PAM VU319 Effects on Network Connectivity in MCI: A POC Study***

Two-time grant winner

Stephen M. Strittmatter, M.D., Ph.D.

Yale University - New Haven, CT

Silent Allosteric Modulation of mGluR5 for Alzheimer's Disease

Raymond Tesi, M.D.

INmune Bio - La Jolla, CA

A Biomarker Directed Study to Reduce Inflammation in Alzheimer's Disease

***Trials or development not advanced*

NEUROINFLAMMATION

A first-of-its kind competition, the Part the Cloud Neuroinflammation Challenge was created to accelerate therapeutics and deepen understanding of neurodegeneration to be used in early clinical trials. Scientists around the world were invited to submit proposals that could translate into human trials of treatments targeting neuroinflammation with the goal of improving cognition in individuals with neurodegenerative diseases.

From 60 proposals submitted from 14 countries, four researchers were awarded \$1 million each to develop their proposals over a two-year period. After two years, projects were evaluated, and the most outstanding project was awarded an additional \$3 million to take it and the field to the next level.

Isidro Ferrer, M.D., Ph.D.

Center for Networked Biomedical Research on Neurodegenerative Diseases - Barcelona, Spain

*Sativex in MCI Patients at High Risk of Developing Alzheimer's Disease***

John M. Olichney, M.D.

University of California at Davis - Davis, CA

Proof of Mechanism Study of Senicapoc in Mild or Prodromal Alzheimer's Disease

Anthony Andrew Oliva, Ph.D.

Longeveron, LLC - Miami, FL

Mesenchymal Stem Cell Therapy for Neuroinflammation in Alzheimer's Disease

Two-time grant winner

Anthony Andrew Oliva, Ph.D.

Longeveron, LLC - Miami, FL

Clinical Evaluation of Allogenic Mesenchymal Stem Cells for Mild Alzheimer's Disease

After two years, this study was shown to have made the most progress and received this additional award of \$3 million.

Huntington Potter, Ph.D.

University of Colorado at Denver - Denver, CO

Safety & Efficacy of GM-CSF/Leukine in Mild-to-Moderate Alzheimer's Disease

***Trials or development not advanced*



This program really knocks innovation out of the ballpark by exploring truly novel mechanisms.”


Paul B. Rosenberg, M.D.

Professor of Psychiatry and Behavioral Sciences at
Johns Hopkins University School of Medicine

PART THE CLOUD AND BILL GATES PARTNERSHIP


In 2019, Part the Cloud announced an exciting partnership with Bill Gates, aiming to double our investment in Alzheimer's research to \$60 million. The Alzheimer's Association, through Part the Cloud, raised over \$20 million and, once we reached that mark, Bill Gates provided a \$10 million match, allowing us to double our clinical research investment to over \$60 million in just one year.

This funding propels high-risk, high-reward research aimed at uncovering underlying brain cell changes, timely diagnosis and new treatments for Alzheimer's and all dementia. The research grants focus on the following three topic areas:



Mitochondria

how brain cells use energy and fuel (mitochondria, bioenergetics and metabolism)



Autophagy / Clearance

how brain cells remove waste and debris to avoid protein clumping



Vascular Contributions

how blood supply in the brain is maintained

From 128 ideas submitted from 18 countries, over \$30 million was awarded to 19 researchers to further develop their research over 3 years.

Elinor Ben Assayag, Ph.D. and Hen Hallevi, M.D.

Tel Aviv Sourasky Medical Center - Tel-Aviv, Israel

Safety and Efficacy of Maraviroc in Vascular Cognitive Impairment

Anat Biegon, Ph.D.

The Research Foundation of SUNY- SUNY at Stony Brook - Stony Brook, NY

Aromatase Inhibition in Alzheimer's Disease: Phase 2 Study

David Celermajer, M.D., Ph.D.

The Brain Protection Company - Paddington, Australia

Phase 1 Study of a Novel Device Reducing Vascular Contributions to Dementia

Hung-Kai (Kevin) Chen, M.D., Ph.D.

Elixiron Immunotherapeutics Inc. - Taipei, Taiwan

CSF1R Inhibitor EI071 for Modulating Microglia-Associated Neuroinflammation

Two-time grant winner

Davangere P. Devanand, M.D.

Research Foundation for Mental Hygiene, Inc. at New York State Psychiatric Institute - New York, NY

Anti-Viral Treatment in Mild Cognitive Impairment

John Didsbury, Ph.D.

T3D Therapeutics, Inc. - Research Triangle Park, NC

The PIONEER Study: A Phase 2 Trial of T3D-959 in Alzheimer's Subjects

Paul Edison, M.B.B.S, F.R.C.P., Ph.D.

Imperial College London -
London, United Kingdom

*Mitochondrial Function and BBB Leakage as a Novel
Treatment for Alzheimer's*

Two-time grant winner

Alireza Faridar, M.D.

The Methodist Hospital Research Institute -
Houston, TX

*Regulatory T cells as a novel therapeutic target in
Alzheimer's Disease*

Nir Grossman, Ph.D.

Imperial College London -
London, United Kingdom

*Non-Invasive Deep Brain Stimulation for
Alzheimer's Disease*

Dan Iosifescu, M.D.

New York University School of Medicine
- New York, NY

*Photobiomodulation for Early Stage Alzheimer
Disease (PhESAD)*

Miia Kivipelto, M.D., Ph.D.

Imperial College London - London,
United Kingdom

*MET- FINGER- APOE: Multimodal Lifestyle
Intervention + Metformin to Prevent
Cognitive Decline*

Krista L. Lanctôt, Ph.D.

Sunnybrook Research Institute - Toronto, Canada

*Exercise as a Primer for Excitatory Stimulation in
VCIND (EXPRESS-V)*

Two-time grant winner

Lyndon Lien, Ph.D., M.B.A.

Qinotto, Inc. - Hillsborough, CA

*Small molecule lysosome activator for the treatment
of neurodegeneration*

Peter Ljubenkov, M.D.

University of California, San Francisco -
San Francisco, CA

*Veri-T: A phase I Placebo-Controlled Trial of
Verdiperstat in FTLD-TDP*

Sudha Seshadri, M.D.

University of Texas Health Science Center at
San Antonio - San Antonio, TX

Phase 2 Trial of Rapamycin for Alzheimer's Disease

Li-Huei Tsai, Ph.D.

Massachusetts Institute of Technology -
Cambridge, MA

*Prevention of Alzheimer's Disease Using
Gamma Entrainment*

Chad Glasser, PharmD

Cyclerion Therapeutics, Inc. - Cambridge, MA

*Phase 2 Study of CNS sGC Stimulation in AD with
Vascular Features*

Thomas Wisniewski, M.D.

New York University School of Medicine -
New York, NY

*Phase 1 Clinical Trial of Innate Immunity Stimulation
via TLR9 in Early AD*

Eti Yoles, Ph.D. and Michal Schwartz, Ph.D.

ImmunoBrain Checkpoint, Inc. - New York, NY

*IBC-Ab002 - Immune Checkpoint Blockade to
Combat Alzheimer's Disease*

THE PART THE CLOUD GENE TARGETING CHALLENGE

Changing the future of Alzheimer's disease? It's in our DNA.



Treatments addressing the unique biological circumstances of each individual with Alzheimer's disease or another disease that causes dementia are the future of treatment.



Though the U.S. Food and Drug Administration (FDA) has approved several treatments for early Alzheimer's, none of them are panacea. Emerging evidence suggests that effective treatment for many individuals is likely to be a combination therapy of two or more drugs targeting distinct biological processes.



A number of factors likely contribute to the development of neurodegenerative disease – a significant factor being genetics.

Part the Cloud has had a close eye on the genetic contributions to Alzheimer's disease since its inception.

One of the first projects funded by Part the Cloud was the Whole Genome Sequencing extension of ADNI, which is sequencing the whole genome of more than 800 individuals. And since then, Part the Cloud has funded several trials that target genes that are implicated in Alzheimer's disease, including:



Ross Paterson, MRCP, Ph.D., at University College London, who is conducting a phase 1b trial to test whether targeting specific genes can lead to the reduction of tau tangles, a hallmark of Alzheimer's disease and many other neurodegenerative diseases.



Mark Tuszynski, M.D., Ph.D., at University of California, San Diego, whose phase 1 gene therapy trial aims to improve the survival and function of brain cells in Alzheimer's disease.



With more than 100 genes associated with the development of Alzheimer’s disease, there is massive potential for personalized gene editing and therapy, and much more clinical research is needed. Part the Cloud recognizes that potential and is doing something about it.

In 2024, Part the Cloud launched its Gene Targeting Challenge, which will fill the gap in Alzheimer’s disease and related dementia clinical trials for advancing potential gene targeting therapeutics forward by providing support for early phase studies. Grants will support new and ongoing early-stage clinical trials using gene targeting.

Awarded studies will be announced in 2025.

FUELING BOLD RESEARCH ACROSS THE GLOBE.

A global research leader, the Alzheimer's Association is at the forefront of groundbreaking research advancing medical precision in the new era of treatments for Alzheimer's.

Please consider making a donation to support Part the Cloud and our mission to find a treatment or cure for Alzheimer's disease in our lifetime.

Learn more and make a donation at
[ALZ.ORG/PARTTHECLOUD](https://alz.org/partthecloud)

Stay up-to-date on the latest from
Part the Cloud and sign up for our monthly newsletter
by visiting our website: alz.org/partthecloud.



ALZHEIMER'S  **ASSOCIATION®**